10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one
Chronic Pain Syndrome
McGill University Health Centre/Research Institute of the McGill University Health CentreSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
91 Active assets in the Chronic Pain Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-Tramadol EMS | Phase 4 | BBB |
Lidocaine National and Kapodistrian University of Athens | Phase 4 | BBB |
Methadone Cari Health Inc. | Phase 4 | BBB |
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Stanford University | Phase 4 | BBB |
Fentanyl Aga Khan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →